lifestyle.newsblaze.com

Author: Nanobiotix S.A.

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

April 20, 2026
Voting Rights and Shares Capital of the Company

April 7, 2026
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

April 1, 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

March 30, 2026
NANOBIOTIX Statement Regarding Recent Media Speculation

March 25, 2026
Voting Rights and Shares Capital of the Company

March 12, 2026
NANOBIOTIX to Participate in Investor Conferences in March

February 25, 2026
Voting Rights and Shares Capital of the Company

February 17, 2026